CoChat

Pharmacological interventions for people with borderline personality disorder

Open access
Stoffers-Winterling, Jutta M, Storebø, Ole Jakob, Pereira Ribeiro, Johanne, Kongerslev, Mickey T, Völlm, Birgit A, Mattivi, Jessica T, Faltinsen, Erlend, Todorovac, Adnan, Jørgensen, Mie S, Callesen, Henriette E, Sales, Christian P, Schaug, Julie Perrine, Simonsen, Erik, Lieb, Klaus · 2022 · Cochrane Database of Systematic Reviews
Cited by 108

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Among people with a diagnosis of borderline personality disorder (BPD) who are engaged in clinical care, prescription rates of psychotropic medications are high, despite the fact that medication use is off-label as a treatment for BPD. Nevertheless, people with BPD often receive several psychotropic drugs at a time for sustained periods. OBJECTIVES: To assess the effects of pharmacological treatment for people with BPD. SEARCH METHODS: For this update, we searched CENTRAL, MEDLINE, Embase, 14 other databases and four trials registers up to February 2022. We contacted researchers working in the field to ask for additional data from published and unpublished trials, and handsearched relevant journals. We did not restrict the search by year of publication, language or type of publication. SELECTION CRITERIA: Randomised controlled trials comparing pharmacological treatment to placebo, other pharmacologic treatments or a combination of pharmacologic treatments in people of all ages with a formal diagnosis of BPD. The primary outcomes were BPD symptom severity, self-harm, suicide-related outcomes, and psychosocial functioning. Secondary outcomes were individual BPD symptoms, depression, attrition and adverse events. DATA COLLECTION AND ANALYSIS: At least two review authors independently selected trials, extracted data, assessed risk of bias using Cochrane's risk of bias tool and assessed the certainty of the evidence using the GRADE approach. We performed data analysis using Review Manager 5 and quantified the statistical reliability of the data using Trial Sequential Analysis. MAIN RESULTS: We included 46 randomised controlled trials (2769 participants) in this review, 45 of which were eligible for quantitative analysis and comprised 2752 participants with BPD in total. This is 18 more trials than the 2010 review on this topic. Participants were predominantly female except for one trial that included men only. The mean age ranged from 16.2 to 39.7 years across the included trials. Twenty-nine different types of medications compared to placebo or other medications were included in the analyses. Seventeen trials were funded or partially funded by the pharmaceutical industry, 10 were funded by universities or research foundations, eight received no funding, and 11 had unclear funding. For all reported effect sizes, negative effect estimates indicate beneficial effects by active medication. Compared with placebo, no difference in effects were observed on any of the primary outcomes at the end of treatment for any medication. Compared with placebo, medication may have little to no effect on BPD symptom severity, although the evidence is of very low certainty (antipsychotics: SMD -0.18, 95% confidence interval (CI) -0.45 to 0.08; 8 trials, 951 participants; antidepressants: SMD -0.27, 95% CI -0.65 to 1.18; 2 trials, 87 participants; mood stabilisers: SMD -0.07, 95% CI -0.43 to 0.57; 4 trials, 265 participants). The evidence is very uncertain about the effect of medication compared with placebo on self-harm, indicating little to no effect (antipsychotics: RR 0.66, 95% CI 0.15 to 2.84; 2 trials, 76 participants; antidepressants: MD 0.45 points on the Overt Aggression Scale-Modified-Self-Injury item (0-5 points), 95% CI -10.55 to 11.45; 1 trial, 20 participants; mood stabilisers: RR 1.08, 95% CI 0.79 to 1.48; 1 trial, 276 participants). The evidence is also very uncertain about the effect of medication compared with placebo on suicide-related outcomes, with little to no effect (antipsychotics: SMD 0.05, 95 % CI -0.18 to 0.29; 7 trials, 854 participants; antidepressants: SMD -0.26, 95% CI -1.62 to 1.09; 2 trials, 45 participants; mood stabilisers: SMD -0.36, 95% CI -1.96 to 1.25; 2 trials, 44 participants). Very low-certainty evidence shows little to no difference between medication and placebo on psychosocial functioning (antipsychotics: SMD -0.16, 95% CI -0.33 to 0.00; 7 trials, 904 participants; antidepressants: SMD -0.25, 95% CI -0.57 to 0.06; 4 trials, 161 participants; mood stabilisers: SMD -0.01, 95% CI -0.28 to 0.26; 2 trials, 214 participants). Low-certainty evidence suggests that antipsychotics may slightly reduce interpersonal problems (SMD -0.21, 95% CI -0.34 to -0.08; 8 trials, 907 participants), and that mood stabilisers may result in a reduction in this outcome (SMD -0.58, 95% CI -1.14 to -0.02; 4 trials, 300 participants). Antidepressants may have little to no effect on interpersonal problems, but the corresponding evidence is very uncertain (SMD -0.07, 95% CI -0.69 to 0.55; 2 trials, 119 participants). The evidence is very uncertain about dropout rates compared with placebo by antipsychotics (RR 1.11, 95% CI 0.89 to 1.38; 13 trials, 1216 participants). Low-certainty evidence suggests there may be no difference in dropout rates between antidepressants (RR 1.07, 95% CI 0.65 to 1.76; 6 trials, 289 participants) and mood stabilisers (RR 0.89, 95% CI 0.69 to 1.15; 9 trials, 530 participants), compa

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd012956.pub2

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Research works printed but not linked: 220

  1. Amminger, 2013, Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial, Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie], 58, 402, 10.1177/070674371305800705 · DOI · Paper page
  2. Van den Broek, 2008, P.3.c.038. The effect of quetiapine on psychotic-like symptoms in borderline personality disorder. A placebo-controlled trial, European Neuropsychopharmacology, 18, S425, 10.1016/S0924-977X(08)70622-9 · doi:10.1016/s0924-977x(08)70622-9
  3. Bellino, 2013, Omega-3 fatty acids associated with valproate in the treatment of borderline personality disorder: a controlled study, Journal of Psychopathology, 19, 296
  4. Bellino, 2014, Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid, Journal of Psychopharmacology, 28, 125, 10.1177/0269881113510072 · DOI
  5. Bozzatello, 2018, Combination of omega-3 fatty acids and valproic acid in treatment of borderline personality disorder: a follow-up study, Clinical Drug Investigation, 38, 367, 10.1007/s40261-017-0617-x · DOI
  6. Bellino S Inclusion of study in Cochrane review Email to: A Tadorovac
  7. Black, 2014, Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial, American Journal of Psychiatry, 171, 1174, 10.1176/appi.ajp.2014.13101348 · DOI · Paper page
  8. Lee, 2016, Quetiapine's effect on the SCL-90-R domains in patients with borderline personality disorder, Annals of Clinical Psychiatry, 28, 4
  9. Bogenschutz, 2004, Olanzapine versus placebo in the treatment of borderline personality disorder, Journal of Clinical Psychiatry, 65, 104, 10.4088/jcp.v65n0118 · DOI · Paper page
  10. Bozzatello, 2017, Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: an open-label randomized controlled trial, Central Nervous System Drugs, 31, 801, 10.1007/s40263-017-0458-4 · DOI
  11. Cowdry, 1988, Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine, Archives of General Psychiatry, 45, 111, 10.1001/archpsyc.1988.01800260015002 · DOI · Paper page
  12. Gardner, 1985, Alprazolam-induced dyscontrol in borderline personality disorder, American Journal of Psychiatry, 142, 98, 10.1176/ajp.142.1.98 · DOI · Paper page
  13. Gardner, 1986, Development of melancholia during carbamazepine treatment in borderline personality disorder, Journal of Clinical Psychopharmacology, 6, 236, 10.1097/00004714-198608000-00008 · DOI
  14. Gardner, 1986, Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder, American Journal of Psychiatry, 143, 519, 10.1176/ajp.143.4.519 · DOI
  15. Crawford, 2015, Lamotrigine versus inert placebo in the treatment of borderline personality disorder: study protocol for a randomized controlled trial and economic evaluation, Trials, 16, 308, 10.1186/s13063-015-0823-x · DOI
  16. Crawford, 2018, Lamotrigine for people with borderline personality disorder: a RCT, Health Technology Assessment, 22, 1, 10.3310/hta22170 · DOI
  17. Crawford MJ Inclusion of your study in Cochrane review Email to: A Pathmanathan Ratnam
  18. De la Fuente, 1994, A trial of carbamazepine in borderline personality disorder, European Neuropsychopharmacology, 4, 479, 10.1016/0924-977x(94)90296-8 · DOI
  19. De la Fuente, 1993, Carbamazepine in borderline personality disorder, European Neuropsychopharmacology, 3, 350, 10.1016/0924-977X(93)90132-6 · DOI
  20. Goldberg, 1986, Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo, Archives of General Psychiatry, 43, 680, 10.1001/archpsyc.1986.01800070070009 · DOI · Paper page
  21. Grant, 2022, A double-blind placebo-controlled study of brexpiprazole for the treatment of borderline personality disorder, British Journal of Psychiatry, 220, 58, 10.1192/bjp.2021.159 · DOI
  22. Hallahan, 2007, Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial, British Journal of Psychiatry, 190, 118, 10.1192/bjp.bp.106.022707 · DOI · Paper page
  23. Hollander, 2001, A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder, Journal of Clinical Psychiatry, 62, 199, 10.4088/jcp.v62n0311 · DOI · Paper page
  24. Jariani, 2010, The effect of olanzapine and sertraline on personality disorder in patients with methadone maintenance therapy, Psychiatria Danubina, 22, 544
  25. Kulkarni, 2018, Effect of the glutamate NMDA receptor antagonist memantine as adjunctive treatment in borderline personality disorder: an exploratory, randomised, double-blind, placebo-controlled trial, Central Nervous System Drugs, 32, 179, 10.1007/s40263-018-0506-8 · DOI
  26. Leone, 1982, Response of borderline patients to loxapine and chlorpromazine, Journal of Clinical Psychiatry, 43, 148
  27. Linehan, 2008, Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study, Journal of Clinical Psychiatry, 69, 999, 10.4088/jcp.v69n0617 · DOI · Paper page
  28. Loew, 2006, Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study, Journal of Clinical Psychopharmacology, 26, 61, 10.1097/01.jcp.0000195113.61291.48 · DOI · Paper page
  29. Loew, 2008, Topiramate treatment of women with borderline personality disorder, part II: an open 18-month follow-up, Journal of Clinical Psychopharmacology, 28, 355, 10.1097/JCP.0b013e318173a8fb · DOI
  30. Markovitz, 1995, Impulsivity and Aggression, 263
  31. Moen, 2012, Efficacy of extended-release divalproex combined with "condensed" dialectical behavior therapy for individuals with borderline personality disorder, Annals of Clinical Psychiatry, 24, 255
  32. Montgomery, 1982, Pharmacological prevention of suicidal behaviour, Journal of Affective Disorders, 4, 291, 10.1016/0165-0327(82)90026-x · DOI · Paper page
  33. Montgomery, 1983, Depression and Suicide: Aspects Medicaux, Psychologiques et Socio-Culturels, 786, 10.1016/B978-0-08-027080-7.50130-0 · DOI
  34. Montgomery, 1982, Pharmacological prevention of suicidal behaviour, Journal of Affective Disorders, 4, 291, 10.1016/0165-0327(82)90026-x · DOI · Paper page
  35. Montgomery, 1983, The prevention of recurrent suicidal acts, British Journal of Clinical Pharmacology, 15, 183, 10.1111/j.1365-2125.1983.tb05864.x · DOI · Paper page
  36. Fertuck, 2012, Higher executive control and visual memory performance predict treatment completion in borderline personality disorder, Psychotherapy and Psychosomatics, 81, 38, 10.1159/000329700 · DOI · Paper page
  37. Nickel, 2007, Topiramate reduced aggression in female patients with borderline personality disorder, European Archives of Psychiatry and Clinical Neuroscience, 257, 432, 10.1007/s00406-007-0735-1 · DOI
  38. Nickel, 2004, Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study, Journal of Clinical Psychiatry, 65, 1515, 10.4088/jcp.v65n1112 · DOI · Paper page
  39. Nickel, 2008, Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up, European Psychiatry, 23, 115, 10.1016/j.eurpsy.2007.09.004 · DOI · Paper page
  40. Nickel, 2005, Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study, Biological Psychiatry, 57, 495, 10.1016/j.biopsych.2004.11.044 · DOI · Paper page
  41. Nickel, 2007, Topiramate treatment of aggression in male borderline patients, Australian and New Zealand Journal of Psychiatry, 41, 461, 10.1080/00048670701261251 · DOI · Paper page
  42. Nickel, 2007, Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up, Psychopharmacology, 191, 1023, 10.1007/s00213-007-0740-0 · DOI
  43. Nickel, 2006, Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study, American Journal of Psychiatry, 163, 833, 10.1176/ajp.2006.163.5.833 · DOI · Paper page
  44. Nickel, 2007, Aripiprazole treatment of patients with borderline personality disorder, Journal of Clinical Psychiatry, 68, 1815, 10.4088/jcp.v68n1124f · DOI
  45. Pascual, 2008, Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study, Journal of Clinical Psychiatry, 69, 603, 10.4088/JCP.v69n0412 · DOI · Paper page
  46. Reich, 2009, A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder, International Clinical Psychopharmacology, 24, 270, 10.1097/YIC.0b013e32832d6c2f · DOI · Paper page
  47. Rinne, 2002, SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder, American Journal of Psychiatry, 159, 2048, 10.1176/appi.ajp.159.12.2048 · DOI · Paper page
  48. Salzmann, 1995, Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder, Journal of Clinical Psychopharmacology, 15, 23, 10.1097/00004714-199502000-00005 · DOI · Paper page
  49. Schmahl, 2012, Evaluation of naltrexone for dissociative symptoms in borderline personality disorder, International Clinical Psychopharmacology, 27, 61, 10.1097/YIC.0b013e32834d0e50 · DOI · Paper page
  50. Schulz, 2006, P02.101 Olanzapine for the treatment of borderline personality disorder: a flexible-dose 12-week randomized double-blind placebo-controlled study, International Journal of Neuropsychopharmacology, 9, S191, 10.1017/S1461145706007292 · doi:10.1017/s1461145706007292
  51. Schulz, 2008, Olanzapine for the treatment of borderline personality disorder: variable dose, 12-week randomised double-blind placebo-controlled study, British Journal of Psychiatry, 193, 485, 10.1192/bjp.bp.107.037903 · DOI · Paper page
  52. Schulz SC Zanarini MC Detke HC Trzaskoma Q Lin D DeBerdt W Olanzapine for the treatment of borderline personality disorder: a flexible-dose, 12-week, randomized, double-blind, placebo-controlled study Association of European Psychiatrsts. 15th European Congress of Psychiatry; 2007 Mar 17-21; Madrid, Spain 2007 · DOI
  53. Schulz, 2007, P248 Olanzapine for the treatment of borderline personality disorder: a flexible-dose 12-week randomized double-blind placebo-controlled study, European Psychiatry, 22, S172, 10.1016/j.eurpsy.2007.01.564 · DOI
  54. Zanarini, 2006, 80. Olanzapine for the treatment of borderline personality disorder: two 12-week randomized double-blind placebo-controlled trials, Neuropsychopharmacology, 31, S229, 10.1017/S1461145706007292 · doi:10.1017/s1461145706007292
  55. Shafti, 2010, Olanzapine versus haloperidol in the management of borderline personality disorder, Journal of Clinical Psychopharmacology, 30, 44, 10.1097/JCP.0b013e3181c826ff · DOI
  56. Shafti, 2015, A comparative study on olanzapine and aripiprazole for symptom management in female patients with borderline personality disorder, Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology], 25, 38, 10.5455/bcp.20140923100030 · doi:10.5455/bcp.20140923100030
  57. Shafti, 2014, Olanzapine vs aripiprazole in the management of borderline personality disorder, Current Psychopharmacology, 3, 132, 10.2174/2211556003666140912223626 · doi:10.2174/2211556003666140912223626
  58. Soloff, 1987, Behavioral dyscontrol in borderline patients treated with amitriptyline, Psychopharmacology Bulletin, 23, 177
  59. Soloff, 1986, Paradoxical effects of amitriptyline on borderline patients, American Journal of Psychiatry, 143, 1603, 10.1176/ajp.143.12.1603 · DOI · Paper page
  60. Soloff, 1986, Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo, Archives of General Psychiatry, 43, 691, 10.1001/archpsyc.1986.01800070081010 · DOI · Paper page
  61. Soloff, 1989, Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response, Journal of Clinical Psychopharmacology, 9, 238, 10.1097/00004714-198908000-00002 · DOI · Paper page
  62. Soloff, 1986, Amitriptyline and haloperidol in unstable and schizotypal borderline disorders, Psychopharmacology Bulletin, 22, 177
  63. Cornelius, 1993, Haloperidol vs phenelzine in continuation therapy of borderline disorder, Psychopharmacology Bulletin, 29, 333
  64. Cornelius, 1993, Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine, American Journal of Psychiatry, 150, 1843, 10.1176/ajp.150.12.1843 · DOI · Paper page
  65. Soloff, 1993, Efficacy of phenelzine and haloperidol in borderline personality disorder, Archives of General Psychiatry, 50, 377, 10.1001/archpsyc.1993.01820170055007 · DOI · Paper page
  66. Leiberich, 2008, Lamotrigine treatment of aggression in female borderline patients, part II: an 18-month follow-up, Journal of Psychopharmacology, 22, 805, 10.1177/0269881107084004 · DOI · Paper page
  67. Tritt, 2005, Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study, Journal of Psychopharmacology, 19, 287, 10.1177/0269881105051540 · DOI · Paper page
  68. Zanarini, 2001, Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study, Journal of Clinical Psychiatry, 62, 849, 10.4088/jcp.v62n1103 · DOI · Paper page
  69. Zanarini, 2003, Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study, American Journal of Psychiatry, 160, 167, 10.1176/appi.ajp.160.1.167 · DOI · Paper page
  70. Zanarini, 2004, A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder, Journal of Clinical Psychiatry, 65, 903, 10.4088/jcp.v65n0704 · DOI · Paper page
  71. Zanarini, 2007, A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo controlled study, European Psychiatry, 22, S172, 10.1016/j.eurpsy.2007.01.565 · DOI
  72. Zanarini MC Schulz SC Detke HC Tanaka Y Zhao F Lin D A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study Association of European Psychiatrists. 15th European Congress of Psychiatry; 2007 Mar 17-21; Madrid, Spain 2007 · DOI
  73. Zanarini, 2006, P02.102 A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized double-blind placebo-controlled study, International Journal of Neuropsychopharmacology, 9, S191, 10.1017/S1461145706007450 · doi:10.1017/s1461145706007450
  74. Zanarini, 2006, 80. Olanzapine for the treatment of borderline personality disorder: two 12-week randomized double-blind placebo-controlled trials, Neuropsychopharmacology, 31, S229, 10.1017/S1461145706007292 · doi:10.1017/s1461145706007292
  75. Ziegenhorn, 2009, Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial, Journal of Clinical Psychopharmacology, 29, 170, 10.1097/JCP.0b013e31819a4bae · DOI · Paper page
  76. Coccaro, 1997, Fluoxetine and impulsive aggressive behavior in personality-disordered subjects, Archives of General Psychiatry, 54, 1081, 10.1001/archpsyc.1997.01830240035005 · DOI · Paper page
  77. Hollander, 2005, Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder, American Journal of Psychiatry, 162, 621, 10.1176/appi.ajp.162.3.621 · DOI · Paper page
  78. Hollander, 2003, Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders, Neuropsychopharmacology, 28, 1186, 10.1038/sj.npp.1300153 · DOI · Paper page
  79. Malevani J AW: Cochrane review: RCT zu Quetapin und Sertraline bei BPS [personal communication] Email to: J Stoffers-Winterling
  80. Koenigsberg, 2003, Risperidone in the treatment of schizotypal personality disorder, Journal of Clinical Psychiatry, 64, 628, 10.4088/jcp.v64n0602 · DOI · Paper page
  81. La Malfa, 2003, Aggressiveness and personality disorders: evaluation of efficacy and existence of predictors in the treatment with fluvoxamine and lithium, Minerva Psychiatrica, 44, 75
  82. Links, 1990, Lithium therapy for borderline patients: preliminary findings, Journal of Personality Disorders, 4, 173, 10.1521/pedi.1990.4.2.173 · DOI · Paper page
  83. Marchesi, 2006, Personality disorders and response to medication treatment in panic disorder: a 1-year naturalistic study, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 30, 1240, 10.1016/j.pnpbp.2006.03.010 · DOI
  84. Goodman M RE: [EXTERNAL] Cochrane Colllaboration review [personal communication] Email to: J Stoffers-Winterling
  85. McCloskey M Fwd: Cochrane Collaboration review - RCT of escitalopram in BPD Email to: J Stoffers-Winterling
  86. Parsons, 1989, Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression, Psychopharmacology Bulletin, 25, 524
  87. Rombold, 2014, Adjunctive lithium treatment in the prevention of suicidal behavior in patients with depression and comorbid personality disorders, International Journal of Psychiatry in Clinical Practice, 18, 300, 10.3109/13651501.2014.940052 · DOI
  88. Russell, 2003, Chronic depression and comorbid personality disorders: response to sertraline versus imipramine, Journal of Clinical Psychiatry, 64, 554, 10.4088/jcp.v64n0510 · DOI · Paper page
  89. Serban, 1984, Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol, American Journal of Psychiatry, 141, 1455, 10.1176/ajp.141.11.1455 · DOI · Paper page
  90. Verkes, 1998, Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression, American Journal of Psychiatry, 155, 543, 10.1176/ajp.155.4.543 · DOI · Paper page
  91. Wollmer, 2022, Clinical effects of glabellar botulinum toxin injections on borderline personality disorder: a randomized controlled trial, Journal of Psychopharmacology, 36, 159, 10.1177/02698811211069108 · DOI
  92. Arteaga-Henríquez, 2020, Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial, Trials, 21, 161, 10.1186/s13063-019-4040-x · DOI
  93. Chanen, 2019, Ripiprazole compared with placebo for auditory verbal hallucinations in youth with borderline personality disorder: protocol for the VERBATIM randomized controlled trial, Early Intervention in Psychiatry, 13, 1373, 10.1111/eip.12774 · DOI
  94. Aguglia, 2021, Off-label use of second-generation antipsychotics in borderline personality disorder: a survey of Italian psychiatrists, Journal of Personality Disorders, 35, 321, 10.1521/pedi_2019_33_445 · DOI
  95. Alvarez-Tomás, 2017, Long-term course of borderline personality disorder: a prospective 10-year follow-up study, Journal of Personality Disorders, 31, 590, 10.1521/pedi_2016_30_269 · DOI · Paper page
  96. Álvarez-Tomás, 2019, Long-term clinical and functional course of borderline personality disorder: a meta-analysis of prospective studies, European Psychiatry, 56, 75, 10.1016/j.eurpsy.2018.10.010 · DOI
  97. Amminger, 2010, Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial, Archives of General Psychiatry, 67, 146, 10.1001/archgenpsychiatry.2009.192 · DOI · Paper page
  98. Andrews, 2013, GRADE guidelines: 15. Going from evidence to recommendation - determinants of a recommendation’s direction and strength, Journal of Clinical Epidemiology, 66, 726-35, 10.1016/j.jclinepi.2013.02.003 · DOI · Paper page
  99. American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders (DSM-III)
  100. American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)
  101. American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
  102. American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)
  103. American Psychiatric Association, 2001, Practice guideline for the treatment of patients with borderline personality disorder, American Journal of Psychiatry, 158, 1
  104. American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders (DSM-5), 10.1176/appi.books.9780890425596 · DOI · Paper page
  105. Atkins, 2004, Grading quality of evidence and strength of recommendations, BMJ, 328, 1490, 10.1136/bmj.328.7454.1490 · DOI · Paper page
  106. Ayodeji, 2015, The influence of personality disorder on outcome in adolescent self-harm, British Journal of Psychiatry, 207, 313, 10.1192/bjp.bp.113.138941 · DOI · Paper page
  107. Barrett, 1995, Personality Characteristics of the Personality Disordered, 91
  108. Bateman, 2015, Treatment of personality disorder, Lancet, 385, 735, 10.1016/S0140-6736(14)61394-5 · DOI · Paper page
  109. Beck, 1961, An inventory for measuring depression, Archives of General Psychiatry, 4, 561, 10.1001/archpsyc.1961.01710120031004 · DOI · Paper page
  110. Bellino S Inclusion of study in Cochrane review Email to: A Tadorovac
  111. Berkey, 1996, Uncertainty of the time of first significance in random effects cumulative meta-analysis, Controlled Clinical Trials, 17, 357, 10.1016/S0197-2456(96)00014-1 · DOI
  112. Bero L Why the Cochrane risk of bias tool should include funding source as a standard item Cochrane Database of Systematic Reviews 2013 12 ED000075 10.1002/14651858.ED000075 24575439 · DOI · Paper page
  113. Biskin, 2015, The lifetime course of borderline personality disorder, Canadian Journal of Psychiatry, 60, 303, 10.1177/070674371506000702 · DOI · Paper page
  114. Black, 2014, Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial, American Journal of Psychiatry, 171, 1174, 10.1176/appi.ajp.2014.13101348 · DOI · Paper page
  115. Bode, 2017, Health care costs of borderline personality disorder and matched controls with major depressive disorder: a comparative study based on anonymized claims data, European Journal of Health Economics, 18, 1125, 10.1007/s10198-016-0858-2 · DOI
  116. Bohus, 2021, Borderline personality disorder, Lancet, 398, 1528, 10.1016/S0140-6736(21)00476-1 · DOI · Paper page
  117. Borschmann, 2012, Crisis interventions for people with borderline personality disorder, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD009353.pub2 · DOI · Paper page
  118. Bridler, 2015, Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders, European Neuropsychopharmacology, 25, 763, 10.1016/j.euroneuro.2015.03.017 · DOI
  119. Brok, 2008, Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses, Journal of Clinical Epidemiology, 61, 763, 10.1016/j.jclinepi.2007.10.007 · DOI · Paper page
  120. Brok, 2009, Apparently conclusive meta-analysis may be inconclusive -- trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses, International Journal of Epidemiology, 38, 287, 10.1093/ije/dyn188 · DOI · Paper page
  121. Brühl, 2017, Neuroscience-based nomenclature: improving clinical and scientific terminology in research and clinical psychopharmacology, Psychological Medicine, 47, 1339, 10.1017/S0033291716003603 · DOI
  122. Brunetti, 2013, GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence, Journal of Clinical Epidemiology, 66, 140-50, 10.1016/j.jclinepi.2012.04.012 · DOI · Paper page
  123. Cailhol, 2015, Mental health service utilization among borderline personality disorder inpatients, L'Encéphale, 41, 115, 10.1016/j.encep.2014.10.008 · DOI
  124. Cavelti, 2019, Preliminary evidence for the cognitive model of auditory verbal hallucinations in youth with borderline personality disorder, Front Psychiatry, 10, 292, 10.3389/fpsyt.2019.00292 · DOI
  125. Cavelti, 2021, Psychotic symptoms in borderline personality disorder: developmental aspects, Current Opinion in Psychology, 37, 26, 10.1016/j.copsyc.2020.07.003 · DOI
  126. Chanen, 2012, Developmental pathways to borderline personality disorder, Current Psychiatry Reports, 14, 45, 10.1007/s11920-011-0242-y · DOI · Paper page
  127. Chanen, 2017, Prevention and early intervention for borderline personality disorder: a novel public health priority, World Psychiatry, 16, 215, 10.1002/wps.20429 · DOI · Paper page
  128. Coccaro, 1991, Development of neuropharmacologically-based behavioral assessments of impulsive aggressive behavior, Journal of Neuropsychiatry and Clinical Neurosciences, 3, S44
  129. Coccaro, 2020, The Overt Aggression Scale Modified (OAS-M) for clinical trials targeting impulsive aggression and intermittent explosive disorder: validity, reliability, and correlates, Journal of Psychiatric Research, 124, 50, 10.1016/j.jpsychires.2020.01.007 · DOI
  130. Crawford M Inclusion of your study in Cochrane review Email to: A Pathmanathan Ratnam
  131. Curtin, 2002, Meta-analysis combining parallel and cross-over clinical trials. III: the issue of carry-over, Statistics in Medicine, 21, 2161, 10.1002/sim.1207 · DOI · Paper page
  132. Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021), Cochrane 2021 Available from www.training.cochrane.org/handbook
  133. Derogatis, 1994, The Use of Psychological Testing for Treatment Planning and Outcome Assessment
  134. Deutsche Gesellschaft für Psychiatrie und Psychotherapie Psychosomatik und Nervenheilkunde (DGPPN) [German Association for Psychiatry, 2009, S2-Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1: Behandlungsleitlinie Persönlichkeitsstörungen [S2 Practical Guidelines in Psychiatry and Psychotherapy. Treatment Guideline Personality Disorders], 1
  135. Eaton, 2018, Personality disorders: community prevalence and socio-demographic correlates, Current Opinion in Psychology, 21, 28, 10.1016/j.copsyc.2017.09.001 · DOI
  136. Ellison, 2018, Community and clinical epidemiology of borderline personality disorder, Psychiatric Clinics of North America, 41, 561, 10.1016/j.psc.2018.07.008 · DOI · Paper page
  137. Gartlehner, 2021, Pharmacological treatments for borderline personality disorder: a systematic review and meta-analysis, Central Nervous System Drugs, 35, 1053, 10.1007/s40263-021-00855-4 · DOI
  138. Gartlehner, 2021, Authors’ reply to Pereira Ribeiro et al: comment on “Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis”, Central Nervous System Drugs, 35, 1335
  139. Goodman, 2012, Suicidal risk and management in borderline personality disorder, Current Psychiatry Reports, 14, 79, 10.1007/s11920-011-0249-4 · DOI
  140. Gunderson, 2011, Borderline personality disorder, New England Journal of Medicine, 364, 2037, 10.1056/NEJMcp1007358 · DOI · Paper page
  141. Guttierez, 2001, Development and initial validation of the Self-Harm Behavior Questionnaire, Journal of Personality Assessment, 77, 475, 10.1207/S15327752JPA7703_08 · DOI · Paper page
  142. Hancock-Johnson, 2017, A focused systematic review of pharmacological treatment for borderline personality disorder, Central Nervous System Drugs, 31, 345, 10.1007/s40263-017-0425-0 · DOI
  143. Hastrup, 2019, Societal costs of borderline personality disorders: a matched-controlled nationwide study of patients and spouses, Acta Psychiatrica Scandinavica, 140, 458, 10.1111/acps.13094 · DOI · Paper page
  144. Herpertz, 2007, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders, World Journal of Biological Psychiatry, 8, 212, 10.1080/15622970701685224 · DOI · Paper page
  145. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  146. Higgins JPT Altmand DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston M, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org/handbook/archive/v5.2
  147. Ingenhoven, 2011, Differential effectiveness of antipsychotics in borderline personality disorder: Meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains, Journal of Clinical Psychopharmacology, 31, 489, 10.1097/JCP.0b013e3182217a69 · DOI
  148. Ingenhoven, 2015, Pharmacotherapy for borderline patients: business as usual or by default?, Journal of Clinical Psychiatry, 76, e522, 10.4088/JCP.14com09522 · DOI
  149. Jacobi, 2021, Disease burden of borderline personality disorder: cost of illness, somatic comorbidity and mortality, Nervenarzt, 92, 660, 10.1007/s00115-021-01139-4 · DOI
  150. Kay, 1987, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, 13, 261, 10.1093/schbul/13.2.261 · DOI · Paper page
  151. Kjaergard, 2001, Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses, Annals of Internal Medicine, 135, 982, 10.7326/0003-4819-135-11-200112040-00010 · DOI · Paper page
  152. Knappich, 2014, Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices, International Clinical Psychopharmacology, 29, 224, 10.1097/YIC.0000000000000021 · DOI
  153. Kongerslev, 2015, Personality disorder in childhood and adolescence comes of age: a review of the current evidence and prospects for future research, Scandinavian Journal of Child and Adolescent Psychiatry and Psychology, 3, 31, 10.21307/sjcapp-2015-004 · DOI · Paper page
  154. 2020, Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project), Systematic Reviews, 9, 1
  155. Lau, 1995, Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care, Journal of Clinical Epidemiology, 48, 45, 10.1016/0895-4356(94)00106-Z · DOI · Paper page
  156. Levine, 1986, SAFTEE: a technique for the systematic assessment of side effects in clinical trials, Psychopharmacology Bulletin, 22, 343
  157. Linehan, 1997, Behavioral treatments of suicidal behaviors: definitional obfuscation and treatment outcomes, Annals of the New York Academy of Sciences, 836, 302, 10.1111/j.1749-6632.1997.tb52367.x · DOI · Paper page
  158. Links, 2009, Essentials of Personality Disorders, 343
  159. Mancke, 2015, Gender differences in aggression of borderline personality disorder, Borderline Personal Disord Emot Dysregul, 9, 7, 10.1186/s40479-015-0028-7 · DOI · Paper page
  160. Meuldijk, 2017, The value of psychological treatment for borderline personality disorder: Systematic review and cost offset analysis of economic evaluations, PLoS One, 1, e0171592, 10.1371/journal.pone.0171592 · DOI · Paper page
  161. Moher, 1999, Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses, Lancet, 354, 1896, 10.1016/S0140-6736(99)04149-5 · DOI · Paper page
  162. Montgomery, 1979, A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
  163. Montgomery, 1983, Dépression et Suicide: Aspects Medicaux, Psychologiques et Socio-Culturels, 786-90, 10.1016/B978-0-08-027080-7.50130-0 · DOI
  164. Mulder, 2021, CD-11 personality disorders: utility and implications of the new model, Front Psychiatry, 12, 655548, 10.3389/fpsyt.2021.655548 · DOI
  165. Munk-Jørgensen, 2010, Use of ICD-10 diagnoses in Danish psychiatric hospital-based services in 2001-2007, World Psychiatry, 9, 183, 10.1002/j.2051-5545.2010.tb00307.x · DOI · Paper page
  166. Neuroscience-Based Nomenclature Neuroscience-Based Nomenclature, Second Edition-reivsed https://nbn2r.com/search
  167. Neacsiu, 2017, Understanding borderline personality disorder across sociocultural groups: findings, issues, and future directions, Current Psychiatry Reviews, 13, 188, 10.2174/1573400513666170612122034 · DOI
  168. Newton-Howes, 2021, Personality disorder prevalence and correlates in a whole of nation dataset, Soc Psychiatry Psychiatr Epidemiol, 56, 679, 10.1007/s00127-020-01876-y · DOI
  169. Ng, 2016, Recovery from borderline personality disorder: a systematic review of the perspectives of consumers, clinicians, family and carers, PLoS One, 11, e0160515, 10.1371/journal.pone.0160515 · DOI
  170. National Health and Medical Research Council, 2013, Clinical Practice Guideline for the Management of Borderline Personality Disorder
  171. Niesten, 2016, Description and prediction of the income status of borderline patients over 10 years of prospective follow-up, Personality and Mental Health, 10, 285, 10.1002/pmh.1331 · DOI · Paper page
  172. Ose, 2021, Non-suicidal self-injury (NSSI) in adult psychiatric outpatients - a nationwide study, Journal of Psychiatric Research, 133, 1, 10.1016/j.jpsychires.2020.11.031 · DOI
  173. Ottosson, 2002, Cross-system concordance of personality disorder diagnoses of DSM-IV and diagnostic criteria for research of ICD-10, Journal of Personality Disorders, 16, 283, 10.1521/pedi.16.3.283.22537 · DOI
  174. Oud, 2018, Specialized psychotherapies for adults with borderline personality disorder: A systematic review and meta-analysis, Aust N Z J Psychiatry, 52, 949, 10.1177/0004867418791257 · DOI · Paper page
  175. Overall, 1962, The Brief Psychiatric Rating Scale, Psychological Reports, 10, 799, 10.2466/pr0.1962.10.3.799 · DOI · Paper page
  176. Paris, 2015, Why patients with severe personality disorders are overmedicated, Journal of Clinical Psychiatry, 76, e521, 10.4088/JCP.14com09441 · DOI
  177. Pascual, 2021, Twenty-Year Trends in the Psychopharmacological Treatment of Outpatients with Borderline Personality Disorder: A Cross-Sectional Naturalistic Study in Spain., CNS Drugs, 35, 1023, 10.1007/s40263-021-00852-7 · DOI
  178. Paton, 2015, The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK Mental Health Services, Journal of Clinical Psychiatry, 76, e512-8, 10.4088/JCP.14m09228 · DOI · Paper page
  179. Comment on: “Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis” CNS Drugs 35 1333 1334 https://doi.org/10.1007/s40263-021-00872-3 · DOI
  180. Perez, 2007, The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes, Actas Españolas de Psiquiatría, 35, 229
  181. Review Manager Web (RevMan Web) The Cochrane Collaboration 2020
  182. Riffer, 2019, Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines, International Journal of Psychiatry in Clinical Practice, 23, 178, 10.1080/13651501.2019.1576904 · DOI
  183. Schneider, 2019, Mortality and medical comorbidity in the severely mentally ill, Deutsches Arzteblatt International, 116, 405, 10.3238/arztebl.2019.0405 · DOI · Paper page
  184. Schulz, 1995, Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials, JAMA, 273, 408, 10.1001/jama.273.5.408 · doi:10.1001/jama.273.5.408
  185. Schulz, 2008, Olanzapine for the treatment of borderline personality disorder: variable dose, 12-week, randomised double-blind placebo-controlled study, British Journal of Psychiatry, 193, 485-92, 10.1192/bjp.bp.107.037903 · DOI · Paper page
  186. Sher, 2019, Gender differences and similarities in aggression, suicidal behaviour, and psychiatric comorbidity in borderline personality disorder, Acta Psychiatr Scand, 139, 145, 10.1111/acps.12981 · DOI
  187. Silk, 2015, Management and effectiveness of psychopharmacology in emotionally unstable and borderline personality disorder, Journal of Clinical Psychiatry, 76, e524-5, 10.4088/JCP.14com09534 · DOI
  188. Soloff, 2002, Childhood abuse as a risk factor for suicidal behavior in borderline personality disorder, Journal of Personality Disorders, 16, 201, 10.1521/pedi.16.3.201.22542 · DOI · Paper page
  189. Soloff, 2012, Prospective predictors of suicidal behavior in borderline personality disorder at 6-year follow-up, Am J Psychiatry, 169, 484, 10.1176/appi.ajp.2011.11091378 · DOI · Paper page
  190. Spielberger, 1988, Manual for the State-Trait Anger Expression Inventory
  191. Stepp, 2012, Development of borderline personality disorder in adolescence and young adulthood: introduction to the special section, Journal of Abnormal Child Psychology, 40, 1, 10.1007/s10802-011-9594-3 · DOI · Paper page
  192. Sterne JA Why the Cochrane risk of bias tool should not include funding source as a standard item Cochrane Database of Systematic Reviews 2013 12 ED000076 10.1002/14651858.ED000076 24575440 · DOI · Paper page
  193. Sterne JAC Egger M Moger D Boutron I Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org/handbook
  194. Stiglmayr, 2005, Aversive tension in patients with borderline personality disorder: a computer-based controlled field study, Acta Psychiatrica Scandinavica, 111, 372, 10.1111/j.1600-0447.2004.00466.x · DOI · Paper page
  195. Stoffers, 2015, Pharmacotherapy for borderline personality disorder--current evidence and recent trends, Current Psychiatry Reports, 17, 534, 10.1007/s11920-014-0534-0 · DOI
  196. Stoffers-Winterling, 2018, Pharmacological interventions for people with borderline personality disorder, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD012956 · DOI
  197. Stoffers-Winterling, 2020, Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies, Current Psychiatry Reports, 22, 37, 10.1007/s11920-020-01164-1 · DOI · Paper page
  198. Stoffers-Winterling J Cochrane Collaboration review - RCT of escitalopram in BPD Email to: E Coccaro
  199. Stone, 1993, Long-term outcome in personality disorders, British Journal of Psychiatry, 162, 299, 10.1192/bjp.162.3.299 · DOI · Paper page
  200. Storebø, 2014, Is ADHD an early stage in the development of borderline personality disorder?, Nordic Journal of Psychiatry, 68, 289, 10.3109/08039488.2013.841992 · DOI · Paper page

200 of 220 shown

Cited by

Metadata

Authors
Stoffers-Winterling, J. M., Storebø, O. J., Pereira Ribeiro, J., Kongerslev, M. T., Völlm, B. A., Mattivi, J. T., Faltinsen, E., Todorovac, A., Jørgensen, M. S., Callesen, H. E., Sales, C. P., Schaug, J. P., Simonsen, E., & Lieb, K.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2022-11-14
Volume
2022
Issue
11
Pages
CD012956-CD012956
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W4308964737
Cited by
108
References
71
FWCI
18.66
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.